Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 10.21 USD 6.47% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

Applied Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Applied Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Pre-Tax Income
-$119.8m
CAGR 3-Years
-8%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
6.73 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Applied Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-119.8m USD

Based on the financial report for Dec 31, 2023, Applied Therapeutics Inc's Pre-Tax Income amounts to -119.8m USD.

What is Applied Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-49%

Over the last year, the Pre-Tax Income growth was -45%. The average annual Pre-Tax Income growth rates for Applied Therapeutics Inc have been -8% over the past three years , -49% over the past five years .

Back to Top